Home
Add Document
Sign In
Create An Account
or Left Main Disease
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With 3-Vessel and/or Left Main Disease On behalf of the...
Author:
Maximillian Harris
2 downloads
2 Views
5MB Size
Report
Download PDF
Recommend Documents
Left main stem coronary artery disease
Coronary Artery Bypass Surgery or Drug Eluting Stent for Unprotected Left Main Coronary Artery Disease
or left
Significant narrowing of the left main (LM)
Horizontal Left or Horizontal Right *)
Long-Term Outcomes in Treating Left Main Trifurcation Coronary Artery Disease with the Paclitaxel-Eluting Stent
or locally advanced disease
The main pathophysiologic feature of Parkinson disease
Left Ventricular Hypertrophy OR Hypertrophic Cardiomyopathy
Simultaneous kissing drug-eluting stents to treat unprotected left main stem bifurcation disease: medium term outcome in 150 consecutive patients
1- Supporting most right to left languages each separately or mixed with English or any left to right languages
LEFT
Left
left
Left
Lyme Disease: Treat, vaccinate, or do nothing?
CELIAC DISEASE, OR gluten-sensitive enteropathy, is
CPPD crystal deposition disease or pseudogout
Autoimmune Pancreatitis: An Autoimmune or Immunoinflammatory Disease?
LEFT VENTRICULAR CARDIOMYOPATHY IN MITRAL VALVE PROLAPSE: FACT OR FICTION?
Celiac Disease versus Gluten Intolerance or Sensitivity
Benefits or Harms of No Child Left Behind
or Moves cursor one position to the left
Testing Whiteness: No Child or No School Left Behind?
Final Five-Year Follow-up of the SYNTAX Trial:
Optimal Revascularization Strategy in Patients With 3-Vessel and/or Left Main Disease On behalf of the SYNTAX investigators
SYNTAX 5-year Outcomes • ESC 2012 • Mohr • August 2012 • Slide 1
SYNTAX Trial Design
62 EU Sites +
23 US Sites
Heart Team (surgeon & interventional cardiologist) Amenable for only one treatment approach
Amenable for both treatment options
Stratification: LM and Diabetes Randomized Arms
Two Registry Arms
N=1800
CABG n=897
3VD
n=549 (66.3%)
vs LM
n=348 (33.7%)
N=1275
TAXUS* n=903
3VD
n=546 (65.4%)
SYNTAX 5-year Outcomes • ESC 2012 • Mohr • August 2012 • Slide 2
LM
n=357 (34.6%)
PCI n=198
CABG n=1077 *
TAXUS Express
Patient Characteristics CABG RCT N=897
PCI RCT N=903
P value
CABG Registry N=644
PCI Registry N=192
Age* (y)
65.0±9.8
65.2±9.7
0.55
65.7±9.4
71.2±10.4
Male, %
78.9
76.4
0.20
80.7
70.3
Diabetes*†, %
24.6
25.6
0.64
26.4
30.2
Additive euroSCORE*
3.8±2.7
3.8±2.6
0.78
3.9±2.7
5.8±3.1
Total Parsonnet score*
8.4±6.8
8.5±7.0
0.76
9.0±7.1
14.4±9.5
29.1±11.4
28.4±11.5
0.19
4.4±1.8
4.3±1.8
0.44
4.6±1.7
4.5±1.8
3VD only, %
66.3
65.4
0.70
59.7
66.7
Left main, any, %
33.7
34.6
0.70
40.3
33.3
Total occlusion, %
22.2
24.2
0.33
56.4
36.5
Complete revasc, %
63.2
56.7
0.005
74.7
36.5
Total SYNTAX Score Mean # of lesions
37.8±13.3 31.6±12.3
Values are mean±SD or %. Core laboratory reported unless *Site-reported †Medically treated
SYNTAX 5-year Outcomes • ESC 2012 • Mohr • August 2012 • Slide 3
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease
SYNTAX 5-year Outcomes • ESC 2012 • Mohr • August 2012 • Slide 4
Patient Disposition to 5 Years 3VD Subset Intent-to-Treat CABG n=549
RCT: Enrolled N=1095
PCI* n=546
CABG n=513
RCT: 1 Year Follow-up CABG 93.4% PCI 98.2%
PCI* n=536
CABG n=505
RCT: 2 Year Follow-up CABG 92.0% PCI 97.6%
PCI* n=533
CABG n=502
RCT: 3 Year Follow-up CABG 91.4% PCI 98.2%
PCI* n=536
CABG n=495
RCT: 4 Year Follow-up CABG 90.2% PCI 97.1%
PCI* n=530
CABG n=483
RCT: 5 Year Final Follow-up CABG 88.0% PCI 96.2%
PCI* n=525
SYNTAX 5-year Outcomes • ESC 2012 • Mohr • August 2012 • Slide 5
*
TAXUS Express
Summary of 1-Year Results P=0.29* 20 7.9% 6.4%
0
0
6 Months Since Allocation
Cumulative Event Rate (%)
Event Rate ± 1.5 SE, *Fisher exact test
12 ITT population
Repeat Revasc.
40
P
Suggest Documents
Left main stem coronary artery disease
Read more
Coronary Artery Bypass Surgery or Drug Eluting Stent for Unprotected Left Main Coronary Artery Disease
Read more
or left
Read more
Significant narrowing of the left main (LM)
Read more
Horizontal Left or Horizontal Right *)
Read more
Long-Term Outcomes in Treating Left Main Trifurcation Coronary Artery Disease with the Paclitaxel-Eluting Stent
Read more
or locally advanced disease
Read more
The main pathophysiologic feature of Parkinson disease
Read more
Left Ventricular Hypertrophy OR Hypertrophic Cardiomyopathy
Read more
Simultaneous kissing drug-eluting stents to treat unprotected left main stem bifurcation disease: medium term outcome in 150 consecutive patients
Read more
1- Supporting most right to left languages each separately or mixed with English or any left to right languages
Read more
LEFT
Read more
Left
Read more
left
Read more
Left
Read more
Lyme Disease: Treat, vaccinate, or do nothing?
Read more
CELIAC DISEASE, OR gluten-sensitive enteropathy, is
Read more
CPPD crystal deposition disease or pseudogout
Read more
Autoimmune Pancreatitis: An Autoimmune or Immunoinflammatory Disease?
Read more
LEFT VENTRICULAR CARDIOMYOPATHY IN MITRAL VALVE PROLAPSE: FACT OR FICTION?
Read more
Celiac Disease versus Gluten Intolerance or Sensitivity
Read more
Benefits or Harms of No Child Left Behind
Read more
or Moves cursor one position to the left
Read more
Testing Whiteness: No Child or No School Left Behind?
Read more
×
Report "or Left Main Disease"
Your name
Email
Reason
-Select Reason-
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Description
×
Sign In
Email
Password
Remember me
Forgot password?
Sign In
Login with Google
Login with Facebook